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A B S T R A C T
Hereditary sensory neuropathy type 1 (HSN-1) is a peripheral neuropathy most frequently caused by mutations
in the SPTLC1 or SPTLC2 genes, which code for two subunits of the enzyme serine palmitoyltransferase (SPT).
SPT catalyzes the ﬁrst step of de novo sphingolipid synthesis. Mutations in SPT result in a change in enzyme
substrate speciﬁcity, which causes the production of atypical deoxysphinganine and deoxymethylsphinganine,
rather than the normal enzyme product, sphinganine. Levels of these abnormal compounds are elevated in blood
of HSN-1 patients and this is thought to cause the peripheral motor and sensory nerve damage that is char-
acteristic of the disease, by a largely unresolved mechanism. In this study, we show that exogenous application
of these deoxysphingoid bases causes dose- and time-dependent neurotoxicity in primary mammalian neurons,
as determined by analysis of cell survival and neurite length. Acutely, deoxysphingoid base neurotoxicity
manifests in abnormal Ca2+ handling by the endoplasmic reticulum (ER) and mitochondria as well as dysre-
gulation of cell membrane store-operated Ca2+ channels. The changes in intracellular Ca2+ handling are ac-
companied by an early loss of mitochondrial membrane potential in deoxysphingoid base-treated motor and
sensory neurons. Thus, these results suggest that exogenous deoxysphingoid base application causes neuronal
mitochondrial dysfunction and Ca2+ handling deﬁcits, which may play a critical role in the pathogenesis of HSN-
1.
1. Introduction
Hereditary sensory neuropathy (HSN) is a group of inherited per-
ipheral nerve disorders, the most common of which, HSN-1, is an au-
tosomal, dominant disease frequently caused by mutations in the genes
encoding serine palmitoyl transferase long chain base subunits 1 and 2
(SPTLC1 and SPTLC2; Dawkins et al., 2001; Nicholson et al., 1996;
Rotthier et al., 2010). HSN-1 is a slowly progressive neuropathy leading
to profound loss of sensation, notably of pain and temperature
(Houlden et al., 2004; Houlden et al., 2006). Despite its classiﬁcation as
a sensory neuropathy, HSN-1 is also associated with variable motor
involvement, ranging from non-existent to severe. Similarly, there is
signiﬁcant diversity in the clinical presentation and age of disease
onset, spanning the second to ﬁfth decades of life (Auer-Grumbach,
2013; Davidson et al., 2012; Houlden et al., 2006; Reilly, 2007; Rotthier
et al., 2012). Symptoms present in the distal limbs, which spread
proximally in a progressive manner. As a result of perturbed sensation,
most patients develop complications, such as recurrent ulcers and os-
teomyelitis, making amputations commonplace (Reilly, 2007). In ad-
dition to the characteristic, progressive loss of sensation, many HSN-1
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patients frequently experience episodes of spontaneous, lancinating,
burning pain (Houlden et al., 2004).
The ubiquitously expressed SPTLC1 (9q22.1–22.3) and SPTLC2
(14q24.3) genes encode two of the three major subunits of the enzyme
serine palmitoyltransferase (SPT, Dawkins et al., 2001; Nicholson et al.,
1996; Rotthier et al., 2010). To date, seven HSN-1-causing missense
mutations in SPTLC1 (Duan and Merrill Jr, 2015; Mroczek et al., 2015)
and seven disease-causing mutations in SPTLC2 have been identiﬁed
(Duan and Merrill Jr, 2015; Mroczek et al., 2015; Suriyanarayanan
et al., 2016). However, despite extensive screening no disease-causing
mutations have been found in the third, SPTLC3-encoded, subunit of
SPT (Rotthier et al., 2010). Clinically, patients with mutations in
SPTLC1 or SPTLC2 are phenotypically indistinguishable and mutations
in both genes have been suggested to cause HSN-1 via the same me-
chanism of dysregulated sphingolipid metabolism (Rotthier et al.,
2012).
SPT is a pyridoxal 5′-phosphate (PLP)-dependent enzyme located on
the outer membrane of the endoplasmic reticulum (ER, Hanada, 2003).
It catalyzes the ﬁrst and rate-limiting step committing substrates to de
novo sphingolipid synthesis, i.e. the condensation of L-serine with pal-
mitoyl-coenzyme A (see Supplementary Fig. S1, Buede et al., 1991;
Hanada et al., 1997; Weiss and Stoﬀel, 1997). Sphingolipids and their
derivatives are not only important structural elements in cell mem-
branes, but also play a central role in signal transduction of external
stimuli towards the nucleus, mediating cell diﬀerentiation, migration
and apoptosis (Fyrst and Saba, 2010). Mutations in numerous enzymes
within the sphingolipid pathway have been associated with neurode-
generation (Kolter and Sandhoﬀ, 2006).
It has previously been shown that HSN-1 mutations alter the sub-
strate speciﬁcity of the SPT enzyme, shifting its preference from the
normal substrate serine to alanine or glycine. The subsequent reactions
produce atypical sphingoid bases: deoxysphinganine (DSp) and deox-
ymethylsphinganine (DMSp), respectively (see Supplementary Fig. S1B
and C, Gable et al., 2010; Penno et al., 2010; Zitomer et al., 2009).
These deoxy-compounds are metabolised to form deoxyceramide and
deoxymethylceramide, which lack the C1 hydroxyl group which is es-
sential for further metabolism into the canonical complex sphingoli-
pids, or indeed for degradation as seen in the typical sphingolipid
pathway (Alecu et al., 2016a; Michel et al., 1997; Steiner et al., 2016).
Elevated levels of deoxysphingoid bases have been detected in HSN-1
patient lymphoblasts and plasma as well as plasma of transgenic mice
expressing mutant SPTLC1 (Auer-Grumbach et al., 2013; Garofalo et al.,
2011; Murphy et al., 2013; Penno et al., 2010; Rotthier et al., 2011;
Suriyanarayanan et al., 2016). Interestingly, elevated levels have also
been detected in the plasma of patients with metabolic syndrome and
type 2 diabetes. Blood deoxysphingolipid levels are also elevated in
animal models of diabetes, for example in the streptozotocin-induced
rat diabetes model and in the leptin-deﬁcient ob/ob mouse (Bertea
et al., 2010; Othman et al., 2014; Othman et al., 2012; Zuellig et al.,
2014). A common complication of diabetes is diabetic neuropathy,
which presents clinically in a very similar manner to HSN-1 (Callaghan
et al., 2012). In addition, cells deprived of serine have also been shown
to generate elevated levels of deoxysphingoid bases (Esaki et al., 2015).
Results from previous studies have suggested that these abnormal
deoxysphingoid bases are harmful to cells, as shown in a number of in
vitromodels (Cuadros et al., 2000; Esaki et al., 2015; Penno et al., 2010;
Salcedo et al., 2007; Zuellig et al., 2014). For example, in avian primary
sensory and motor neurons in vitro, treatment with DSp was found to
cause a dose-dependent decrease in neurite branching, indicative of
neuronal toxicity (Penno et al., 2010). Additional toxic eﬀects of ab-
normal sphingoid bases were also reported in these chick neurons, in-
cluding reduced neurite outgrowth, retraction of existing neurites and
disturbed actin-neuroﬁlament interactions (Penno et al., 2010).
Although several lines of evidence now show that exposure to these
abnormal deoxsphingoid bases causes morphological changes, the cel-
lular pathomechanisms that underlie these toxic eﬀects remain
unresolved. Previous studies have examined the molecular targets of
deoxysphingoid bases primarily in cell lines (Alecu et al., 2016b;
Cuadros et al., 2000; Gable et al., 2010; Salcedo et al., 2007; Sayano
et al., 2016). Exogenous application of DSp to cell lines resulted in an
upregulation of the ER stress markers GADD153 (Gable et al., 2010)
and spliced X-box binding protein 1 (XBP1, Alecu et al., 2016b). In
addition to showing that exogenous DSp treatment causes ER stress,
Alecu et al. (2016b) also showed that DSp application causes both
morphological and functional mitochondrial changes. Findings in HSN-
1 patient lymphoblasts further suggest that mitochondrial abnormal-
ities may play a role in HSN-1 pathology (Myers et al., 2014; Stimpson
et al., 2015).
However, fewer studies have examined the eﬀects of deoxy-
sphingoid base targets in neuronal cells (Alecu et al., 2016b; Guntert
et al., 2016). Alecu et al. (2016b) demonstrated that exogenous appli-
cation of DSp to primary DRG cells resulted in mitochondrial swelling.
Moreover, studies in mammalian cortical neurons suggest there may be
an interaction between DSp and N-methyl-D-aspartate (NMDA) receptor
signalling (Guntert et al., 2016).
In this study, we set out to examine whether exogenous deoxy-SPT
products are neurotoxic to primary mammalian neurons by measuring
parameters indicative of cell viability, including neurite outgrowth and
cell survival. Moreover, we also explore the potential pathomechanisms
underlying such neurotoxicity by examining intracellular Ca2+ hand-
ling and mitochondrial function in both mammalian primary motor and
sensory neurons in vitro.
2. Materials and methods
Animals were sacriﬁced by Schedule 1 methods as outlined in the
UK Animals (Scientiﬁc Procedures) Act (1986), and approved by the
UCL Institute of Neurology Animal Welfare Ethical Review Board. All
reagents were obtained from ThermoFisher Scientiﬁc unless otherwise
speciﬁed.
2.1. Primary mixed motor neuron cultures
For primary mixed motor neuron (MN) cultures, the ventral spinal
cord was dissected from embryonic day 12.5–13.5 (E12.5-E13.5) mouse
embryos (C57BL/6 J, Charles River Laboratories). Ventral horns were
digested in trypsin (0.025%) for 10 mins at 37 °C. The tissue was then
triturated in DNAse I (0.1 mg/ml, Sigma) in 0.4% bovine serum al-
bumin (BSA) in Leibovitz's L15 medium. Supernatant was collected and
the remaining pellet triturated a second time in DNAse I (0.02mg/ml)
in 0.4% BSA in Leibovitz's L15 medium. Supernatants from both tri-
turation steps were combined and centrifuged through a BSA cushion
(4% in Leibovitz's L15 medium) at 380×g for 5 mins to pellet cells. The
supernatant was discarded and the cell pellet re-suspended in supple-
mented neurobasal medium containing 2% B27 supplement, 0.5 mM
GlutaMAX, 25 μM 2-mercaptoethanol, 2% horse serum, 0.1 ng/ml
murine glial cell line-derived neurotrophic factor (GDNF, Peprotech),
0.5 ng/ml human or rat ciliary neurotrophic factor (CNTF by
Peprotech), 0.1 ng/ml human brain-derived neurotrophic factor (BDNF,
Peprotech) and penicillin/streptomycin (50 units per ml/50 μg per ml).
Cells were plated onto 24-well plates with glass coverslips at a cell
density of 5×104 cells/well for cell survival and neurite outgrowth
assays. For live-cell imaging, cells were plated onto glass bottom dishes
(35mm petri dish with 14mm microwell, MatTek) at a cell density of
1× 105 cells/well or 8 well μ-slides (Ibidi) at a cell density of 3× 104
cells/well. All culture dishes were pre-coated overnight with poly-L-
ornithine (3 μg/ml, Sigma) followed by laminin (5 μg/ml, Sigma) for
2 h, prior to seeding cells. These mixed ventral horn cultures were
maintained in supplemented neurobasal medium (as above), under
standard culture conditions (37 °C, 5% CO2). MNs were considered
immature after 1 day in vitro (DIV) and mature after 5 or more DIV, due
to their general morphology as well as the expression of key MN
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characteristics, such as expression of glutamate receptors (Van Den Van
Den Bosch et al., 2000).
2.2. Primary dorsal root ganglia cultures
For primary dorsal root ganglia (DRG) cultures, DRG were harvested
from 3 to 8 day old mice (C57BL/6). Spinal columns were removed, the
DRG exposed and dissected into sterile HBSS (Ca2+ and Mg2+ free)
supplemented with penicillin/streptomycin (100 units per ml/100 μg
per ml). Dissected ganglia were then incubated in pre-warmed HBSS
(Ca2+ and Mg2+ free) containing 60 units of papain (Sigma) at 37 °C for
10min with gentle rotation. Papain solution was then removed and
ganglia re-suspended in pre-warmed HBSS containing collagenase type
II (0.1%) and dispase (1.5 units/ml) at 37 °C for 45min with gentle
rotation. DRG were then gently triturated in order to dissociate them
into a cell suspension. Cells were plated onto glass bottom dishes
(35mm petri dish with 14mm microwell) or 8 well μ-slides (Ibidi) pre-
coated with poly-D-lysine (100 μg/ml, Sigma) and laminin (5 μg/ml).
Mixed DRG cultures were cultured in neurobasal medium supple-
mented with B27 supplement (2%), fetal calf serum (1%), 2mM
GlutaMAX, mouse nerve growth factor (50 ng/ml, Promega) and peni-
cillin/streptomycin (50 units per ml/50 μg per ml). DRG cells were in-
cubated under standard culture conditions (37 °C, 5% CO2) and used for
experiments after 3–5 DIV.
2.3. Drug treatments
Metabolites of SPT enzyme products were purchased from Avanti
Polar Lipids and dissolved in ethanol as stock solutions (1 mM). Cells at
diﬀerent stages after plating were either left untreated or treated with
sphinganine (Sp), deoxysphinganine (DSp), deoxymethylsphinganine
(DMSp) or ethanol (as a vehicle control, 0.1%), at ﬁnal concentrations
ranging from 0.1 μM to 10 μM. The duration of treatment ranged from
5min to 6 days, as described in Results. In some experiments, cultures
were co-treated with 1 μM cyclosporine A (CsA, Sigma), a mitochon-
drial permeability transition pore (mPTP) blocker.
2.3.1. Immunocytochemistry
For cell survival and neurite outgrowth assays, at the end of each
treatment regime, the cells were ﬁxed in 4% paraformaldehyde for
20min then washed in phosphate buﬀered saline (PBS). Prior to pri-
mary antibody labelling, cells were permeabilised in PBS containing
0.1% Triton X-100 (Sigma) and blocked in 5% goat serum. Mouse anti-
β-III tubulin (BioLegend 801201) was used as a pan-neuronal marker
(1:1000), followed by Alexa Fluor® 488 labelled anti-mouse IgG
(H+L) secondary antibody (1:1000, raised in goat). DAPI (1:2000,
Sigma) was used to stain nucleic acids (nuclei).
2.3.2. Cell survival and neurite outgrowth assays
Cultures were immunostained for the neuronal marker anti-β-III
tubulin and stained with the nuclear marker DAPI. The cells were then
imaged using the 20× objective of a Leica epiﬂuorescence light
microscope and the Leica Application Suite software. Images were
taken for cell and neurite counts, as well as assessment of neurite
length. A minimum of ﬁve representative images measuring
655× 491 μm were taken per condition, per experiment. Cells positive
for β-III tubulin and DAPI counter-stain were counted as neurons to
establish the total number of cells surviving. Neurite outgrowth was
assessed by tracing from the cell body to neurite tip. When branched,
the longest neurite was measured and the shorter branch counted as a
separate neurite.
2.3.3. Intracellular Ca2+ measurements
Cultures were washed in recording medium (156mM NaCl, 10mM
HEPES, 10mM D-glucose, 3 mM KCl, 2 mM MgSO4, 2mM CaCl2,
1.25mM KH2PO4, pH 7.35) and then loaded with 5 μM fura-2 AM
(Molecular Probes by Life Technologies) in the above recording
medium supplemented with pluronic F127 (0.04%), for 30min, at room
temperature. Fura-2 was then replaced with recording medium and dye
accumulation optically detected by charge-coupled device (CCD)
camera microscopy following excitation at wavelengths 340 nm and
380 nm using the computer programme Andor iQ 1.9 Imaging. The
ratio of fura-2 emission at 510 nm following excitation at 340/380 nm
wavelengths was used as a readout measure of intracellular Ca2+
concentration; thus, an increase in this ratio signiﬁes an increase in free
Ca2+ present. Relative ER Ca2+ concentration and mitochondrial Ca2+
concentration were measured in Ca2+-free recording medium con-
taining 0.5mM EGTA, ﬁrst using thapsigargin (10 μM, Sigma) to esti-
mate ER Ca2+ (Michelangeli and East, 2011), followed by ionomycin
treatment (10 μM, Sigma), to estimate mitochondrial Ca2+ (Abramov
and Duchen, 2003). Under these conditions ionomycin application re-
sults in the release of Ca2+ from intracellular Ca2+ stores, including
mitochondria. Other cellular compartments also release Ca2+ following
ionomycin application but the greatest contribution is likely to come
from mitochondria (Abramov and Duchen, 2003). Membrane depolar-
ization was achieved using a high potassium-containing (135mM KCl)
recording medium. Store-operated Ca2+ channel entry was measured
using thapsigargin (10 μM) in Ca2+-free recording medium, followed by
replacement with standard, Ca2+-containing recording medium. In
some experiments, 1 μM carbonyl cyanide-p-tri-
ﬂuoromethoxyphenylhydrazone (FCCP, Sigma) was introduced 2 mins
prior to thapsigargin treatment and included in recording media
throughout the experiment in order to render mitochondria non-func-
tional and to test the contribution of mitochondrial Ca2+ buﬀering to
the overall intracellular Ca2+ increase. Relative ER Ca2+, mitochon-
drial Ca2+, membrane-depolarization induced Ca2+ inﬂux and store-
operated Ca2+ entry were all calculated by subtracting the baseline
fura-2 ratio from the relevant peak amplitude fura-2 concentration. The
drugs and conditions used to manipulate intracellular Ca2+ handling
are summarised in Table 1. In all experiments, dying or dead cells not
responding to treatment were excluded from the analysis.
Table 1
Drugs used to explore intracellular Ca2+ handling: The Table summarises the treatments used to measure physiological Ca2+ handling parameters.
Drug Target of drug Experimental condition Physiological measurement
Thapsigargin SERCA pump inhibitor Ca2+-free recording medium ER [Ca2+]
Apply in Ca2+-free recording medium and then re-introduce
Ca2+ to the external medium
SOC channel entry
Ionomycin Non-selective ionophore Apply after thapsigargin, in Ca2+-free recording medium [Ca2+] in mitochondrial and other
intracellular stores
135mM [K+] Plasma membrane depolarization Normal recording medium Membrane-depolarization induced Ca2+
inﬂux
FCCP Protonophore to abolish mitochondrial
membrane potential
Apply FCCP throughout the experiment To determine mitochondrial contribution
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2.3.4. Measurement of mitochondrial membrane potential (Δψm) and total
mitochondrial area
Primary cultures at 5–8 days in vitro (DIV) (MNs) or 3–5 DIV (DRG
neurons) were treated with the sphingoid bases for 2 h prior to live cell
imaging. Cultures were loaded with tetramethylrhodamine methyl ester
(TMRM) (20 nM) in recording medium (as described above) supple-
mented with pluronic F127 (0.04%), for 30min, at room temperature
before imaging (no washes were performed prior to imaging).
Immediately before imaging, cells were additionally loaded with the
live-cell labelling dye calcein blue, AM (1 μM). Z-stack images were
taken on Zeiss Laser Scanning 710 (MNs) or 780 (DRG neurons) con-
focal microscopes using the lasers 405 nm and 561 nm and the ZEN LE
Digital Imaging 2009 or 2012 software. Z-stacks (minimum 720×720
pixels and 12 bit depth) were compressed to maximal intensity per pixel
and thresholded (separately to select for either TMRM signal solely
from mitochondria or calcein blue signal) using ImageJ version 1.51n.
In processed images calcein blue was used to outline individual cells.
TMRM intensity (as a readout measure for Δψm) was calculated from
the cell soma and expressed as a percentage relative to the mean TMRM
intensity in control cells, for each independent imaging session. Total
mitochondrial area (determined using TMRM) was expressed as a per-
centage of the cell soma size (determined using calcein blue), from
thresholded images as described above.
2.3.5. Statistical analysis
Statistical analyses were performed using GraphPad Prism Version
6.0. Data were assumed to be normally distributed unless evidence was
provided otherwise by the D'Agostino-Pearson normality test. Thus,
statistical signiﬁcance was determined by one- or two-way ANOVA with
Dunnett's multiple comparison tests, Kruskal-Wallis with Dunn's mul-
tiple comparison tests, unpaired t-test or Mann-Whitney test, as ap-
propriate. * P < 0.05, ** P < 0.01 and *** P < 0.001.
3. Results
To determine whether abnormal deoxysphingoid bases are neuro-
toxic to mammalian motor neurons, which together with sensory neu-
rons are typically aﬀected in HSN-1, primary motor neuron cultures
(MNs) were treated with either the normal enzymatic product sphin-
ganine (Sp), the atypical products, deoxysphinganine (DSp) and deox-
ymethylsphinganine (DMSp), or a vehicle control (ethanol), at a range
of concentrations and for varying treatment durations. The concentra-
tions chosen were based on deoxysphingoid base concentrations pre-
viously measured in HSN-1 patient plasma (Auer-Grumbach et al.,
2013; Murphy et al., 2013; Penno et al., 2010; Rotthier et al., 2011;
Suriyanarayanan et al., 2016).
3.1. Deoxysphingoid bases are toxic to mammalian motor neurons
Previous studies have shown that atypical sphingoid bases have
deleterious eﬀects on immature primary chick MNs when treated
within the ﬁrst 24 h of plating, causing decreased neurite outgrowth
(Penno et al., 2010). Therefore, in this study we ﬁrst examined the
eﬀects of 24 h sphingoid base treatments on neurite outgrowth in im-
mature mouse MNs at 1 day in vitro (DIV) by immunostaining for the
neuronal marker β-III tubulin. Fig. 1A–D shows representative ex-
amples of mouse MNs treated with vehicle, or 1 μM Sp, DSp or DMSp for
24 h; the measurement criteria used for neurite outgrowth assays are
illustrated in Panel A. Compared to untreated neurons, ethanol treat-
ment alone caused an increase in average and longest neurite lengths
(Supplementary Fig. S2). Therefore, in all subsequent experiments the
eﬀects of sphingoid base treatments on neurite outgrowth were com-
pared to vehicle controls.
3.2. Deoxysphingoid bases reduce neurite outgrowth in motor neurons
The average neurite length was decreased in MNs treated with Sp,
DSp and DMSp, and this eﬀect was exacerbated by increasing con-
centrations (Fig. 1E). Indeed, DSp treatment at a concentration as low
as 0.1 μM, signiﬁcantly decreased average neurite length, from
30.4 ± 1.3 μm in vehicle controls (indicated by the dotted line in
Fig. 1E) to 23.7 ± 1.4 μm in DSp-treated cells (P < 0.05). Although
no signiﬁcant decrease in MN neurite length was observed with 0.1 μM
DMSp treatment, cells treated with 1 μM DMSp had a reduced neurite
length of 27.2 ± 2.0 μm (P < 0.001). In 1 μM DSp-treated cells MN
neurite length was further decreased to 12.9 ± 1.1 μm (P < 0.001).
Interestingly, treatment with the typical enzyme product, Sp, was also
moderately toxic, with 2 μM treatment causing a small but signiﬁcant
decrease (to 28.5 ± 2.3 μm) in average MN neurite length (P < 0.01).
A similar pattern of toxicity was observed when the longest neurite
length per MN was examined (Fig. 1F).
The number of neurites per MN was also assessed, as an indication
of neuronal maturation (Fig. 1G–H). Following treatment with in-
creasing concentrations (0.1–2 μM) of DSp or DMSp, there was an in-
crease in the number of neurons with no neurites (Fig. 1G) and a de-
crease in the number of neurons with two or more neurites (Fig. 1H),
indicating that deoxysphingoid base treatments have detrimental ef-
fects on neuronal complexity. Following treatment with 1 μM DSp,
46 ± 10% of MNs had no neurites and 24 ± 9% of MNs had two or
more neurites. This contrasts to vehicle treated cultures, in which only
9 ± 2% of MNs had no neurites and the majority of MNs, 72 ± 3%,
had a more complex dendritic arborisation pattern, with at least two or
more neurites.
In summary, treatment with DSp and DMSp causes a rapid and dose-
dependent reduction in neurite outgrowth in primary MNs in vitro
(Fig. 1A–D), manifesting both as a decrease in neurite length (Fig. 1E–F)
and a decrease in the number of neurite projections (Fig. 1G–H) when
compared to vehicle treated controls.
3.3. Deoxysphingoid bases cause motor neuron death
The eﬀect of increasing concentrations of sphingoid bases on MN
survival was also determined. In these experiments, the number of β-III
tubulin+ cells in each culture was counted and expressed as a percen-
tage of MN survival in control cultures. Previous studies have shown
that treatment of immature (< 1 DIV) chick neurons (DRG neurons and
MNs) with deoxysphingoid bases for a short period (24 h) results in
neuronal toxicity, as determined by assessment of neurite outgrowth
(Penno et al., 2010); however, this study did not assess the eﬀect on
neuronal survival. In the present study, we therefore ﬁrst established
whether a similar treatment regime was suﬃciently toxic to mamma-
lian MNs to aﬀect neuronal survival. We also examined the eﬀects of
longer treatment durations, as well as the eﬀects on more mature (5
DIV) MNs.
At 1 DIV, MN cultures were treated for 24 h with increasing con-
centrations of Sp, DSp and DMSp (Fig. 2E). Following 24 h treatment
with 2 μM DSp and DMSp, MN survival was reduced to 28 ± 15%
(P < 0.05) and 37 ± 10% (P < 0.05), respectively.
As shown in the representative images in Fig. 2A–D, longer term
treatment of immature MNs (at 1 DIV) with deoxysphingoid bases re-
sulted in a dramatic loss of MNs. Notably, in this long-term, 6 day
treatment paradigm (indicated in the schematic in the upper panel of
Fig. 2F), the signiﬁcant loss of MNs was also accompanied by death of
non-neuronal cells such as ﬁbroblasts, so that few DAPI+, β-III tubulin−
cells were observed. The extent of MN survival was quantiﬁed, and a
dose-dependent decrease in MN survival was observed in response to
DSp and DMSp treatments (Fig. 2F). In cultures treated with 1 μM DSp
or DMSp, only 13 ± 7% (P < 0.05) and 19 ± 9% (P < 0.05) of MNs
survived, respectively.
Since MNs at 1 DIV are relatively immature, the eﬀect of sphingoid
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base treatments on more mature MN cultures was also examined, by
treating MNs at 5 DIV for 4 days (shown in the schematic in the upper
panel of Fig. 2G). This was the longest treatment period possible in
primary MN cultures, since even untreated MNs begin to deteriorate in
culture past 10–14 DIV. These more mature MNs also displayed sus-
ceptibility to deoxysphingoid base toxicity and in this treatment para-
digm, only 36 ± 15% (P < 0.05) and 51 ± 20% (P < 0.05) of MNs
survived following 1 μM DSp and DMSp treatments, respectively.
These results show that the abnormal enzyme products DSp and
DMSp, cause a dose-dependent toxicity in immature and mature cul-
tured primary MNs.
Fig. 1. Treatment with deoxysphingoid bases reduce neurite outgrowth in primary motor neurons, in a dose-dependent manner.
(A-D) Primary MNs were grown for 24 h and then treated with either vehicle (ethanol) or with sphingoid bases. The number of neurites per neuron was counted as
indicated and neurite length was measured by tracing neurites, as illustrated by the dotted line in (A). The cells were stained for DAPI (blue) and immunostained for
β-III tubulin (green). Scale bar= 25 μm. Treatment with the deoxysphingoid bases reduces (E) the average neurite length, and (F) the average length of the longest
neurite, in a dose-dependent manner. In E and F the black dotted line indicates the average or average longest neurite length of MNs treated with an ethanol vehicle
control. These data are not normally distributed and thus displayed statistics indicate comparisons to vehicle control using Kruskal-Wallis (P < 0.001) and Dunn's
multiple comparisons tests. Two-way ANOVA was also performed on the average neurite length (P < 0.001, concentration, P < 0.001, treatment, P < 0.001,
interaction) and longest neurite length (P < 0.001, concentration, P < 0.001, treatment, P < 0.001, interaction). (G) The percentage of MNs with no neurite
outgrowth following treatment with the sphingoid bases at a range of concentrations. The percentages of neurons with no neurite outgrowth were compared to
vehicle controls using two-way ANOVA and Dunnett's multiple comparison test: P < 0.001, concentration, P < 0.001, treatment, P < 0.05, interaction. (H) The
percentage of MNs with 2 or more neurites following treatment with the sphingoid bases at a range of concentrations. The percentages of neurons with no neurite
outgrowth were compared to vehicle controls using two-way ANOVA and Dunnett's multiple comparison test: P < 0.001, concentration, P < 0.001, treatment,
P < 0.001, interaction. Error bars represent S.E.M. P values: * < 0.05; ** < 0.01; *** < 0.001. n= 18–383 cells per condition, from 3 to 5 independent ex-
periments.
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3.4. Deoxysphingoid bases cause abnormal Ca2+ handling in motor and
sensory neurons
Having established that deoxysphingoid base treatments are toxic to
mammalian neurons, we next examined the potential mechanisms un-
derlying the potent neurotoxicity of these abnormal enzyme products.
Since immature MNs (1 DIV) die rapidly upon exposure to deoxy-
sphingoid bases, within 24 h (Fig. 2E), it is diﬃcult to dissect the me-
chanisms underlying cytotoxicity in these cells using this experimental
protocol. Therefore, in the following experiments, designed to examine
the underlying pathomechanisms of deoxysphingoid base neurotoxi-
city, only more mature MNs (≥5 DIV) were examined. Moreover,
mature MNs do not show the increased vulnerability to the normal
enzyme product, Sp, observed in immature MNs (Fig. 2).
3.5. Deoxysphingoid bases have no eﬀect on resting cytosolic Ca2+
SPT is an ER membrane protein and it is well known that the ER
plays a major role in cellular Ca2+ homeostasis. Since changes in in-
tracellular Ca2+ levels are an important early indicator of cell stress
(Mattson, 2000; Trump and Berezesky, 1995), we used the ratiometric
dye fura-2 to examine intracellular Ca2+ in neurons treated with the
deoxysphingoid bases.
Mature MNs (≥5 DIV) were treated acutely for 2 h with 1 μM of
sphingoid bases, and the eﬀects on baseline cytosolic Ca2+ levels were
determined. Following 2 h treatment with either DSp or DMSp there
was no signiﬁcant diﬀerence in resting cytosolic Ca2+ levels
(Supplementary Fig. S3A; fura-2 ratio: 0.77 ± 0.01 in DSp treated cells
and 0.73 ± 0.01 in DMSp treated cells compared to vehicle-treated
cells (ratio: 0.77 ± 0.01)), indicating that short-term treatment with
deoxysphingoid bases does not alter resting cytosolic Ca2+ homeostasis
and these MNs appear largely healthy.
3.6. Deoxysphingoid bases cause rapid depletion of ER Ca2+ in motor and
sensory neurons
Although resting cytosolic Ca2+ levels were not altered by acute
exposure to deoxysphingoid bases, it is possible that this is the result of
eﬀective Ca2+ buﬀering by intracellular organelles, such as the ER and
mitochondria. We therefore examined the eﬀects of deoxysphingoid
base treatments on ER Ca2+. Mature MNs (≥ 5 DIV) were ﬁrst treated
for 24 h with 1 μM deoxysphingoid bases and relative ER Ca2+ levels
determined by measuring the change in cytosolic Ca2+ following
treatment with the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA)
pump inhibitor, thapsigargin, which causes the ER to release Ca2+ into
the cytosol. As these experiments were performed in the absence of
extracellular Ca2+ the resulting change in cytosolic Ca2+ can be used to
infer a relative ER Ca2+, as shown in a typical Ca2+ recording ex-
periment shown in Fig. 3A. Treatment of MNs with deoxysphingoid
bases caused a signiﬁcant reduction in the relative ER Ca2+ in MNs.
Thus, in DSp treated MNs the fura-2 ratio for relative ER Ca2+ was
reduced to 0.15 ± 0.02 compared to 0.22 ± 0.02 in the vehicle
treated MNs (P < 0.05), indicative of ER stress (Fig. 3B). In order to
determine if ER stress is an early event in deoxysphingoid base-medi-
ated neurotoxicity, we shortened the treatment paradigm to just 2 h.
Intriguingly, 2 h treatment with the typical enzyme product, Sp, caused
Fig. 2. Treatments with deoxysphingoid bases reduce survival of primary motor neurons, in a dose-dependent manner.
(A-D) Representative images of primary MNs grown for 24 h before being treated with either (A) vehicle (ethanol) control, (B) Sp, (C) DSp or (D) DMSp. MNs were
ﬁxed and stained with DAPI (blue) and immunostained for β-III tubulin (green) 6 days following treatment, at 7 DIV. Scale bar= 50 μm. (E) MN survival following
treatment at 1 DIV for 24 h, with diﬀerent doses of sphingoid bases, expressed as a percentage relative to control. MN survival was compared to survival in vehicle
treated cultures using two-way ANOVA and Dunnett's multiple comparison test: P < 0.05, concentration, P < 0.01, treatment, P=0.792, interaction. (F) MN
survival following treatment at 1 DIV for 6 days, with diﬀerent doses of sphingoid bases, expressed as a percentage relative to the untreated control. MN survival was
compared to survival in vehicle treated cultures using two-way ANOVA and Dunnett's multiple comparison test: P < 0.01, concentration, P < 0.001, treatment,
P=0.393, interaction. (G) MN survival following treatment at 5 DIV for 4 days, with diﬀerent doses of sphingoid bases, expressed as a percentage relative to the
untreated control. MN survival was compared to survival in vehicle treated cultures using two-way ANOVA and Dunnett's multiple comparison test: P < 0.01,
concentration, P < 0.05, treatment, P < 0.05, interaction. The black dotted lines in E-G represent MN survival in vehicle treated cultures. Error bars represent
S.E.M. P values: * < 0.05; ** < 0.01. n= 4–6 independent experiments per condition.
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a signiﬁcant decrease in the relative ER Ca2+ levels, whereas the
deoxysphingoid bases caused only non-signiﬁcant reductions in the
relative ER Ca2+ to 0.23 ± 0.02 and 0.22 ± 0.03 in DSp and DMSp
treated cells, respectively, in comparison to 0.29 ± 0.03 in vehicle
treated cells (Fig. 3C). Notably, treatment with deoxysphingoid bases
over this 2 h time frame did not cause any change in SPTLC1 protein
expression levels (Supplementary Fig. S4).
We next investigated whether treatment with deoxysphingoid bases
(caption on next page)
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also induces ER stress in primary sensory DRG cells. In DRG cultures
treated for 2 h with deoxysphingoid bases, we observed a dramatic
reduction in the relative ER Ca2+ compared to vehicle-treated DRG
neurons (Fig. 3D); DRG neurons treated with 1 μM DSp or DMSp dis-
played a relative ER fura-2 ratio of 0.61 ± 0.14 and 0.46 ± 0.09,
respectively, in contrast to vehicle-treated DRG neurons, which had a
relative ER fura-2 ratio of 1.50 ± 0.29.
A comparison of the results from MNs and DRG neurons suggests
that deoxysphingoid bases may induce ER stress more readily in DRG
neurons than in MNs, with deoxysphingoid base-induced ER stress
evident in DRG neurons after 2 h treatment, yet similar depletion of
relative ER Ca2+ in MNs was observed only after 24 h treatment.
However, there was a clear diﬀerence between the relative ER Ca2+
levels measured in these two cell types, so that the relative ER Ca2+ was
substantially higher in DRG neurons (1.50 ± 0.29, Fig. 3D) than in
MNs (0.29 ± 0.03, Fig. 3C), which may allow us to detect changes in
Ca2+ more readily than in MNs. Despite this, a direct comparison of ER
Ca2+ levels in the two populations of neurons may not be appropriate
as these neurons have a number of key diﬀerences, for example their
size, excitability and indeed Ca2+ buﬀering capacity.
3.7. Deoxysphingoid bases cause mitochondrial Ca2+ loading in motor
neurons
Since mitochondria also play an important role in the regulation of
intracellular Ca2+ in neurons, mitochondrial Ca2+ levels were also
examined. Mitochondrial Ca2+ was estimated using thapsigargin and
the ionophore, ionomycin, in the absence of extracellular Ca2+ (as in-
dicated in the experiment shown in Fig. 3A). This technique allows an
estimation of mitochondrial Ca2+ to be made (Abramov and Duchen,
2003; Hoek et al., 1995). However, it should be noted that although the
ER contribution to the ionomycin-induced peak is largely eliminated
due to advanced emptying of the ER Ca2+ stores with thapsigargin, it is
possible that intracellular organelles distinct from the ER and the mi-
tochondria may also provide a minor contribution of Ca2+. Following
2 h treatment of MNs with the sphingoid bases, there was a signiﬁcant
elevation in mitochondrial Ca2+ (Fig. 3E). In vehicle treated MNs, the
mitochondrial fura-2 ratio was 0.41 ± 0.05, but this ratio more than
doubled in DSp-and DMSp-treated MNs to 1.14 ± 0.16 (P < 0.001)
and 1.15 ± 0.14 (P < 0.001), respectively. This shift towards higher
mitochondrial Ca2+ was also observed, to some extent, in Sp-treated
MNs, which had an average fura-2 ratio of 0.80 ± 0.13 (P < 0.01).
In contrast, in DRG neurons, the same 2 h treatment regime had no
eﬀect on mitochondrial Ca2+ levels (Fig. 3F), so that in DSp-treated
DRG neurons, the average mitochondrial Ca2+ concentration was
1.38 ± 0.35 compared to 1.23 ± 0.19 in vehicle-treated DRG neu-
rons. However, as observed with ER Ca2+ levels, mitochondrial Ca2+
levels in control DRG cells were substantially higher than in control
MNs (compare Fig. 3E and F).
3.8. Cell membrane depolarization-induced Ca2+ inﬂux is unaﬀected in
deoxysphingoid base-treated motor neurons
We next investigated the source of the increased mitochondrial
Ca2+ observed following acute, 2 h treatment of MNs with the sphin-
goid bases. Firstly, we considered whether the elevated Ca2+ levels
might be a consequence of changes at the cell membrane. We therefore
investigated the eﬀect of deoxysphingoid base treatments on membrane
depolarization-induced Ca2+ inﬂux, such as those through voltage-
gated Ca2+ channels. In these experiments, potassium was used to
depolarize the plasma membrane, thus triggering the opening of vol-
tage-gated Ca2+ channels. As can be seen in Fig. 4A, we observed no
diﬀerence in the fura-2 ratios representing membrane depolarization-
induced Ca2+ inﬂux, between the vehicle control (2.11 ± 0.08), and
any of the sphingoid base treatments; Sp (2.11 ± 0.05), DSp
(2.11 ± 0.05), DMSp (2.24 ± 0.10).
3.9. DSp causes increased store-operated Ca2+ (SOC) channel entry
Next, we examined whether the observed increase in mitochondrial
Ca2+ might originate from a second class of cell membrane channels,
by examining entry of Ca2+ through the ER-regulated store-operated
Ca2+ (SOC) channels. These plasma membrane channels are regulated
by intracellular Ca2+ levels, namely the ER (Putney et al., 2016). To
investigate SOC channel entry, thapsigargin was used to empty Ca2+
from the ER, which in turn results in the opening of SOC channels on
the cell membrane, in a bid to replenish the ER Ca2+ stores, as shown in
experiments depicted in Fig. 4B and C. Thus, when the external Ca2+-
free medium was replaced with Ca2+-containing medium, the inﬂux of
Ca2+ through SOC channels was measured. As can be seen in Fig. 4D,
treatment of MNs with DSp for 2 h resulted in an increase in Ca2+ inﬂux
through SOC channels compared to vehicle control treated MNs, with a
fura-2 ratio of 1.00 ± 0.06 and 0.67 ± 0.05 respectively
(P < 0.001). Frequently, we also observed ﬂuctuation in fura-2 ratios
in DSp-treated MNs following Ca2+ inﬂux through SOC channels when
compared to vehicle treated MNs (Fig. 4C). This may be indicative of
dysregulation of these channels or other disruption at the cell mem-
brane and, indeed, biochemical studies of the properties of deoxy-
sphingoid bases and their derivatives propose that these compounds
may have the ability to aﬀect normal cell membrane function (Jimenez-
Rojo et al., 2014). It is unlikely that the abnormal sphingolipids have an
acute eﬀect on SOC channels directly, since acute, 5 min treatment does
not cause any change in cytosolic fura-2 ratios in these cells, indicating
that DSp and DMSp, in the absence of SOC channel stimulation, do not
have a direct agonist eﬀect on these channels (see Supplementary
Fig. 3B–C).
In order to further conﬁrm that the elevated mitochondrial Ca2+
observed in deoxysphingoid base-treated MNs is due, at least in part, to
dysfunctional SOC entry, FCCP was used to render the mitochondria
dysfunctional prior to measuring SOC entry, which prevents mi-
tochondria from contributing to changes in Ca2+. FCCP is an un-
coupling agent which abolishes the mitochondrial membrane potential
Fig. 3. Treatments with deoxysphingoid bases cause depletion of ER Ca2+ and mitochondrial Ca2+ loading in neurons.
(A) A typical trace (from a MN culture) indicating how thapsigargin and ionomycin were used to estimate ER and mitochondrial Ca2+ levels. (B) At 5–8 DIV, MNs
were treated with either vehicle control (ethanol) or the sphingoid bases for 24 h prior to live cell imaging. Thapsigargin was used to estimate ER Ca2+. Average ER
Ca2+ was established from 42 to 55 cells per condition, from 4 to 5 independent experiments. (P < 0.001, Kruskal-Wallis). (C) At 5–8 DIV, MNs were treated with
either vehicle (ethanol) or the sphingoid bases for 2 h prior to live cell imaging, and as above, thapsigargin used to estimate the ER Ca2+. Average ER Ca2+ was
established from 94 to 184 cells, from 11 to 16 independent experiments. (P=0.003, Kruskal-Wallis). (D) At 3–5 DIV, DRG neurons were treated for 2 h with either
vehicle control (ethanol) or the sphingoid bases for 24 h prior to live cell imaging. Thapsigargin was used to estimate ER Ca2+ and average ER Ca2+ was established
from 28 to 38 cells, from 3 to 4 independent experiments. (P < 0.001, Kruskal-Wallis). (E) At 5–8 DIV, MNs were treated for 2 h prior to live cell imaging.
Thapsigargin and ionomycin were used to estimate mitochondrial Ca2+. Average mitochondrial Ca2+ was established from 36 to 44 cells per condition, from 4 to 5
independent experiments. (P < 0.001, Kruskal-Wallis). (F) At 3–5 DIV, DRG cultures were treated with either vehicle control (ethanol) or the sphingoid bases for 2 h
prior to live cell imaging. Mitochondrial Ca2+ was estimated as above, and average mitochondrial Ca2+ was established from 32 to 41 cells per condition, from 4
independent experiments. (P=0.063, Kruskal-Wallis). Error bars represent S.E.M. For statistical comparison, each treatment group was compared to vehicle control
using Kruskal-Wallis and Dunn's multiple comparisons tests. P values: * < 0.05; ** < 0.01; *** < 0.001.
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by allowing hydrogen ions through the inner mitochondrial space be-
fore they can be used for ATP generation by complex V (Benz and
McLaughlin, 1983). The results summarised in Fig. 4E, show that when
the mitochondrial membrane potential (Δψm), and therefore active
mitochondrial regulation of cytosolic Ca2+, is abolished with FCCP,
there is an increase in cytosolic Ca2+ following opening of SOC
(caption on next page)
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channels. This increased cytosolic Ca2+ after SOC channel activation
was present to similar extents in both vehicle- and DSp- treated MNs,
with the fura-2 ratio changing from 0.67 ± 0.05 to 1.11 ± 0.0.13
(P < 0.01) in vehicle-treated MNs and from 1.00 ± 0.06 to
1.40 ± 0.11 (P < 0.05) in DSp-treated MNs. Application of FCCP led
to exacerbated cytosolic Ca2+ levels in both vehicle-treated and DSp-
treated MNs, providing evidence for an active involvement of mi-
tochondria in Ca2+ buﬀering following SOC channel activation in these
cells.
Taken together, these results suggest that a critical eﬀect of deox-
ysphingoid bases, or their downstream metabolites, may be to alter the
cell membrane, which results in dysregulation of SOC channels, which
in turn aﬀects mitochondrial Ca2+ levels and disturbs ER Ca2+.
3.10. Deoxysphingoid bases cause mitochondrial dysfunction in motor and
sensory cells
Having observed mitochondrial Ca2+ loading in MNs treated
acutely with the deoxysphingoid bases, we next tested whether these
treatments also cause a more generalized mitochondrial dysfunction.
We investigated changes in mitochondrial membrane potential (Δψm)
following 2 h sphingoid base treatments using TMRM, a cationic dye
which accumulates in mitochondria as a function of Δψm, in both MN
and DRG cultures (Fig. 5A and D, respectively). Following treatment
with DSp and DMSp there was a signiﬁcant decrease in Δψm, so that the
mean TMRM intensity declined to 79 ± 2% (P < 0.001) and
74 ± 3% (P < 0.001) of the intensity measured in vehicle treated
neurons, respectively (Fig. 5B). In this short 2 h treatment paradigm,
the decrease in Δψm was not suﬃcient to aﬀect the total mitochondrial
area, expressed as a percentage of the cell soma size (Fig. 5C).
In parallel, DRG neurons subjected to the same treatment paradigm
also displayed a reduced Δψm, with DSp-treated DRG neurons having an
average TMRM intensity 68 ± 3% of the intensity measured in vehicle-
treated DRG neurons (Fig. 5E, P < 0.001). DMSp-treated DRG neurons
showed a similar decrease in Δψm and intriguingly, even treatment with
the typical enzyme product, Sp, caused a depletion in Δψm. In these
sensory DRG cells, 2 h treatment with DSp was also suﬃcient to cause a
decrease in the mitochondrial area per cell soma, so that DSp-treated
DRG neurons showed an average mitochondrial area of 56 ± 3%
compared to 70 ± 3% in vehicle-treated DRG neurons (P < 0.01,
Fig. 5F). The decrease in Δψm observed in these experiments, along
with a reduced total mitochondrial area in DRG cells following such
short-term treatment with the deoxysphingoid bases, supports the hy-
pothesis that neuronal mitochondria are an early target of deoxy-
sphingoid base-mediated neurotoxicity.
A major pathway for cell death that occurs secondary to mi-
tochondrial dysfunction is the opening of the mitochondrial perme-
ability transition pore (mPTP). The mPTP opens in a bid to release
mitochondrial Ca2+, which in turn signals cell death via the con-
comitant release of cytochrome C and pro-caspases in order to trigger
apoptosis (Susin et al., 1999a; Susin et al., 1999b). To explore whether
the opening of the mPTP is responsible for the deoxysphingoid base-
mediated neuronal death we observed in this study (Fig. 2), we co-
treated MNs with cyclosporine A (CsA), an inhibitor of mPTP opening
(Bernardi et al., 1994), alongside the sphingoid bases.
Immature MNs were treated with CsA (1 μM) and the sphingoid
bases (1 μM) for 24 h, and cell survival was expressed as a percentage of
untreated cultures. There was no signiﬁcant diﬀerence in MN survival
in cultures treated with the sphingoid bases alone or with addition of
CsA (Fig. 6); 47 ± 9% of MNs survived in 1 μM DSp-treated cultures,
compared to 41 ± 17% in DSp+CsA-treated cultures. These results
suggest that cell death caused by exogenous application of deoxy-
sphingoid bases is not mediated by mitochondrial permeability transi-
tion.
4. Discussion
In this study we set out to investigate the intracellular eﬀects of
exogenous deoxysphingoid bases, the abnormal enzyme products of
mutant SPT in HSN-1, on cultured mammalian neurons. Our results
clearly show that deoxysphingoid bases are toxic to primary mamma-
lian neurons. Toxicity by these abnormal sphingoid bases manifests as
reduced neurite length and complexity of treated primary MNs (Fig. 1)
as well as a dramatic, dose-dependent reduction in cell survival (Fig. 2).
We also demonstrated that primary MNs are vulnerable to exogenous
application of deoxysphingoid bases both when they are immature and
growing, as well as at more mature stages when these cells already have
extensive dendritic networks.
The concentration range of the deoxysphingoid bases used in these
experiments were conducted within the reported blood plasma levels of
deoxysphingoid bases in HSN-1 patients (Auer-Grumbach et al., 2013;
Garofalo et al., 2011; Murphy et al., 2013; Penno et al., 2010; Rotthier
et al., 2011; Suriyanarayanan et al., 2016). Using these concentrations,
the level of toxicity of DSp and DMSp observed in this in vitro model of
HSN-1 is dramatic, with over 50% of neurons dying after just 1 day of
treatment. This is in contrast to the slowly progressing neuropathy
observed in HSN-1 patients. However, DSp displayed a more severe
pathology than DMSp at the same concentrations tested, as measured
by neurite outgrowth assays, which does reﬂect the higher serum levels
of DSp than DMSp measured in patients. Although the primary em-
bryonic MNs used in these experiments may be particularly vulnerable
to toxicity, it is possible that in vivo, in patients, the blood plasma may
act as a “dumping ground” for deoxysphingoid bases and derivatives,
whereas levels in the immediate vicinity of neurons might be lower.
Moreover, in blood, deoxysphingoid bases are mainly transported on
low and very low density lipoproteins and may be complexed with
other proteins, which could additionally dampen their toxic eﬀects
(Bertea et al., 2010).
In order to elucidate the early, underlying mechanisms involved in
the toxicity of deoxysphingoid bases and to identify speciﬁc targets, we
used short, 2 and 24 h treatment regimens and identiﬁed mitochondria
and ER as early targets of deoxysphingoid base toxicity.
Although an increase in cytosolic Ca2+ is a well-established in-
dicator of cell stress leading to cell death, short-term (2 h) treatment did
not result in any change in resting cytosolic Ca2+ levels
(Supplementary Fig. S4). This suggests that following a 2 h treatment
Fig. 4. Deoxysphingaine causes dysregulation of store-operated Ca2+ (SOC) channels.
(A-E) At 5–8 DIV, MNs were treated with vehicle control or sphingoid bases 2 h prior to live cell imaging with fura-2. (A) High potassium was used to depolarize the
plasma membrane potential and trigger opening of voltage-gated Ca2+ channels. Average membrane depolarization-induced Ca2+ inﬂux per cell was calculated from
23 to 52 cells per condition, from 2 to 3 independent experiments. (P=0.743, one-way ANOVA). (B-E) SOC channel entry was measured using thapsigargin and
subsequent introduction of Ca2+ to the external recording medium. (B-C) Example traces showing SOC channel entry in vehicle (B) and DSp (C) treated cells. Each
diﬀerentially shaded line represents a diﬀerent cell. Arrowheads in Fig. 4C indicate subsequent inﬂuxes of Ca2+ following the initial SOC channel peak inﬂux in the
DSp-treated MNs. (D) Average Ca2+ entry through SOC channels was calculated from 36 to 97 cells per condition, from 5 to 9 independent experiments. (P < 0.001,
Kruskal-Wallis). (E) SOC channel entry was measured with and without co-treatment with FCCP. The average SOC channel Ca2+ inﬂux was established from 38 to 97
cells per condition, from 4 to 9 independent experiments. Error bars represent S.E.M. For statistical comparison, each treatment group was compared to vehicle
control, unless otherwise indicated. Data following Gaussian distribution was compared to vehicle control using One-way ANOVA and Dunnett's multiple com-
parisons tests. Non-normally distrusted data was compared to vehicle control using Kruskal-Wallis and Dunn's multiple comparisons tests. Pairwise comparisons were
made using Mann-Whitney tests. P values: * < 0.05; ** < 0.01; *** < 0.001.
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Fig. 5. Treatments with deoxysphingoid bases reduce the mitochondrial membrane potential.
(A) At 5–8 DIV MNs were treated with sphingoid bases or vehicle control (ethanol) for 2 h prior to live cell imaging. (B) Average TMRM ﬂuorescent intensities per cell
were measured from 26 to 48 MNs per condition, from 3 independent experiments. (P < 0.001, one-way ANOVA). (C) The total mitochondrial area per MN cell body
was also calculated and expressed as a percentage of the cell soma size. (P=0.267, one-way ANOVA). (D) At 3–5 DIV DRG neurons were treated with vehicle control
(ethanol) or sphingoid bases 2 h prior to live cell imaging. (E) Average TMRM ﬂuorescent intensities per cell were measured from 29 to 61 cells, from 4 independent
experiment. (P < 0.001, one-way ANOVA). (F) The total mitochondrial area per DRG cell body was also calculated and expressed as a percentage of the cell soma
size. (P=0.017, one-way ANOVA). Error bars represent S.E.M. For statistical comparison, each treatment group was compared to vehicle control. Data was
compared to vehicle control using one-way ANOVA and Dunnett's multiple comparisons tests. ns= not signiﬁcant. P values: * < 0.05; ** < 0.01; *** < 0.001.
Scale bars= 10 μm.
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paradigm, MNs were functioning, are able to compensate for any da-
maging eﬀects of the treatment and are not yet undergoing apoptosis.
This experimental model therefore oﬀers an opportunity to probe the
underlying mechanisms of deoxysphingoid base toxicity.
The ER is a key organelle for the regulation of cellular Ca2+
homeostasis and the SPT enzyme is located in the ER membrane; the ER
is thus the site of deoxysphingoid base generation. We observed Ca2+
depletion in the ER, indicative of ER stress, as early as 2 h in DRG cells,
yet in MNs, which intrinsically appear to store less Ca2+ in ER and
mitochondria than sensory neurons, there was no measurable depletion
of Ca2+ in the ER at this time point (Fig. 3C–D). However, ER stress
does become apparent at a later stage in MNs, measured in our ex-
periments as a depletion of relative ER Ca2+ after 24 h of treatment
with the deoxysphingoid bases (Fig. 3B). Our ﬁnding that deoxy-
sphingoid bases may aﬀect motor and sensory neurons diﬀerentially, or
at least the eﬀects may develop on a diﬀerent time scale, is in line with
the clinical manifestation of the disease; typically, HSN-1 patients
present with sensory deﬁcits in advance of motor deﬁcits (Reilly, 2007).
Mitochondria also play a major role in buﬀering cellular Ca2+ and
mitochondrial abnormalities have been reported in several studies in
HSN-1 patient lymphoblasts, as well as in cells treated exogenously
with DSp (Alecu et al., 2016b; Myers et al., 2014; Stimpson et al.,
2015). Moreover, the mitochondrial outer membrane associates with
the ER, where SPT localizes, via the mitochondria-associated ER
membrane (MAM, Csordas et al., 2006). The MAM is known to play an
important role in intermembrane transport of phospholipids as well as a
potential role in the transport of ceramide (Hayashi et al., 2009), a
downstream component of the de novo sphingolipid synthesis pathway,
the pathway speciﬁcally aﬀected by HSN-1-causing mutations. In this
study, 2 h treatment with the sphingoid bases caused a shift towards
elevated mitochondrial Ca2+ in MNs, but not in sensory neurons
(Fig. 3E–F). It could be speculated that elevated mitochondrial Ca2+ is
a very early event in deoxysphingoid base-mediated toxicity, which
precedes depletion of ER Ca2+ (seen only after 24 h treatment in MNs),
and thus the 2 h treatment model used in these experiments is not
suﬃciently short to capture changes in mitochondrial Ca2+ in DRG
cells, in which depletion of ER Ca2+ is evident much earlier than in
MNs. However, diﬀerences in the experimental setup used to measure
relative ER Ca2+ in DRGs and MNs make it diﬃcult to draw direct
comparisons between the two cell types. MNs are developmentally
younger when the relative ER Ca2+ content is measured as they are
derived from embryonic mouse spinal cords, whereas DRG cells are
obtained from postnatal mice and this developmental shift might be
responsible for the observed diﬀerences between relative ER Ca2+
measured in motor and sensory neurons. The proposal that mitochon-
drial Ca2+ levels may be aﬀected in advance of ER Ca2+ levels mirrors
the recent study of Alecu et al. that tracked deoxysphinagnines to the
mitochondria within 5 mins of application, and at later time points, also
to the ER (Alecu et al., 2016b).
Extracellular treatment of MNs with deoxysphingoid bases leads to a
rapid loading of Ca2+ into mitochondria, while resting cytosolic Ca2+
and relative ER Ca2+ are both unaﬀected following short-term (2 h)
treatment. Thus, the most obvious source of Ca2+ is the extracellular
space through speciﬁc cationic channels: voltage-gated channels,
second messenger-operated channels, receptor-operated channels,
store-operated channels, or under some conditions, the reversal of the
sodium-Ca2+ exchanger (NCX, Parekh and Putney Jr, 2005). In this
study we tested two major groups of cationic channels that could be
responsible; activity-dependant voltage-gated ion channels and the
store-operated Ca2+ (SOC) channels that are regulated by the ER,
causing the opening of these channels upon Ca2+ store depletion.
Membrane depolarization-induced inﬂux of Ca2+ was measured after
2 h treatment with sphingoid bases, and no diﬀerence was detected
between the control and any of the treatment groups, indicating that
the deoxysphingoid bases do not directly interfere with this element of
normal neuronal activity, at least not at this early phase (Fig. 4A).
Another source of extracellular Ca2+ is via the SOC channels. The
primary role of these channels is to replenish ER Ca2+ stocks. A second
major destination of Ca2+ inﬂux through these channels is mitochon-
dria (Malli et al., 2003) and thus, it is possible that the Ca2+ inﬂux
induced by opening of SOC channels immediately loads into mi-
tochondria. We observed that a short, 2 h treatment regime with DSp
caused a highly signiﬁcant increase in Ca2+ inﬂux through SOC chan-
nels (Fig. 4D). Not only did we observe an increase in the amount of
Ca2+ entry from the extracellular space in DSp-treated cells, but we also
frequently observed a ﬂuctuation of Ca2+ levels, instead of the rela-
tively smooth decline of Ca2+ entry observed in control cells after the
initial Ca2+ inﬂux (Fig. 4C). Moreover, when mitochondrial Ca2+ up-
take was abolished with FCCP, we observed an increase in SOC inﬂux
into the cytosol in both control and DSp-treated cells (Fig. 4E). Thus, a
major destination of Ca2+ ﬂowing through the SOC channels in these
cells is indeed mitochondria, but in the absence of mitochondrial buf-
fering, Ca2+ remains in the cytosol. Taken together, these ﬁndings
suggest that a source of elevated mitochondrial Ca2+ in DSp-treated
neurons may be, at least in part, dysfunctional SOC channels. Inter-
estingly, dysregulation of SOC channels has also been implicated in
another inherited peripheral neuropathy, Charcot-Marie-Tooth disease,
secondary to GDAP1 mutations (Barneo-Munoz et al., 2015; Gonzalez-
Sanchez et al., 2017; Pla-Martin et al., 2013).
Elevated mitochondrial Ca2+ levels are damaging to mitochondria
and usually result in cell stress and, if the Ca2+ loading persists, can
lead to apoptosis. In our experiments, elevated mitochondrial Ca2+ in
MNs was recorded, alongside a reduction in mitochondrial membrane
potential, which was displayed in both MNs and DRG neurons, even
after only 2 h of treatment with deoxysphingoid bases (Fig. 5B and E).
In addition to a depletion of mitochondrial membrane potential, 2 h
DSp treatment was also suﬃcient to cause a decrease in the total mi-
tochondrial area in DRG cells, but not in MNs (Fig. 5C and F). Indeed
this provides further evidence that MNs and DRG neurons may respond
diﬀerently to DSp or DMSp treatments or within diﬀerent time frames,
as is reﬂected in the clinical progression of HSN-1 in patients where
sensory function is aﬀected earlier than motor. Mitochondrial Ca2+
loading, as well as loss of mitochondrial membrane potential are known
to cause opening of the mitochondrial permeability transition pore
Fig. 6. Treatment with cyclosporine A (CsA) is not suﬃcient to rescue deoxy-
sphingoid base mediated neuronal death.
After 24 h in vitro, MNs were treated with either Sp, DSp or DMSp alone or in
combination with 1 μM CsA. MNs were ﬁxed 24 h following treatment, at 2 DIV,
and stained with DAPI and β-III tubulin for analysis. MN survival is expressed as
a percentage relative to untreated controls. Statistical analysis was performed
using two-way ANOVA: P=0.041, treatment, P=0.491, CsA treatment,
P=0.741, interaction. N=4–10 independent experiments per condition. Error
bars represent S.E.M. ns= not signiﬁcant.
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(mPTP, Norenberg and Rao, 2007; Szabo and Zoratti, 1992). However,
in this study, co-treatment with an mPTP blocker, cyclosporine A (CsA),
did not alleviate deoxysphingoid base-mediated neuronal death
(Fig. 6). We therefore propose that the elevation in mitochondrial Ca2+
observed in this study is a transient change occurring rapidly in re-
sponse to exogenous deoxysphingoid base application. Thus cell death
as a result of deoxysphingoid base application appears here to be in-
dependent of mPTP-mediated apoptosis.
DSp, but not DMSp, treatment caused elevated SOC entry in cul-
tured MNs (Fig. 4B) as well as depleted mitochondrial membrane po-
tential and total mitochondrial area in DRG neurons (Fig. 5E–F). This
suggests that there may be some functional diﬀerences in how DSp and
DMSp toxicity manifests, and indeed this may provide reason for the
more ready manifestation of DSp toxicity, when compared to DMSp
(Fig. 1E–F). There are studies suggesting that neurotoxicity by DSp and
DMSp might be mediated by their downstream metabolites (Alecu
et al., 2016b; Guntert et al., 2016). In this study we focused exclusively
on the physiological eﬀects of extracellular DSp and DMSp application,
establishing a link between these abnormal sphingolipids, Ca2+ reg-
ulation and mitochondrial function.
In conclusion, the results of this study demonstrate that exogenous
application of deoxysphingoid bases is toxic to mammalian neurons,
manifesting in reduced neurite outgrowth and decreased neuronal
survival. Moreover, we also demonstrate that ER and mitochondrial
dysfunction may play early roles in deoxysphingoid base-induced
neurotoxicity, well before any neuronal death occurs. Depleted ER
Ca2+ and mitochondrial Ca2+ loading, together with a reduction in
mitochondrial membrane potential, occur rapidly after treatment with
deoxysphingoid bases in cultured neurons. Moreover, the increase in
mitochondrial Ca2+ loading may be a result of dysregulation of SOC
channels located on the cell membrane. As these abnormalities occur at
a very early stage, when morphologically these cells appear normal and
no cell loss has occurred, it is likely that the observed Ca2+ and mi-
tochondrial changes are part of the primary mechanism leading to the
eventual neuronal death. Identiﬁcation of key signalling pathways
leading to deoxysphingolipid-mediated neurotoxicity may help reveal
targets for therapeutic intervention in HSN-1, in a bid to slow or pre-
vent peripheral nerve damage.
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